Pharmazz India Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 4.81 Cr
as on 16-11-2024
- Company Age 13 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 50.80%
(FY 2023)
- Profit 261.02%
(FY 2023)
- Ebitda 330.67%
(FY 2023)
- Net Worth 5.26%
(FY 2023)
- Total Assets 5.35%
(FY 2023)
About Pharmazz India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 4.81 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sunil Gulati, Anil Gulati, Lov Verma, and One other member serve as directors at the Company.
- CIN/LLPIN
U24100DL2011FTC215954
- Company No.
215954
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
16 Mar 2011
- Date of AGM
10 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Pharmazz India Private Limited offer?
Pharmazz India Private Limited offers a wide range of products and services, including Diagnostic Imaging & Pathology Labs, Medical Test Services, First Aid Kits, Shock Treatment Chart.
Who are the key members and board of directors at Pharmazz India?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manish Lavhale  | Managing Director | 14-Aug-2021 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sunil Gulati | Director | 16-Mar-2011 | Current |
| Lov Verma | Director | 04-Feb-2017 | Current |
Anil Gulati  | Director | 16-Mar-2011 | Current |
Financial Performance and Corporate Structure Insights of Pharmazz India.
Pharmazz India Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 50.8% increase. The company also saw a substantial improvement in profitability, with a 261.02% increase in profit. The company's net worth moved up by a moderate rise of 5.26%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pharmazz India?
In 2023, Pharmazz India had a promoter holding of 79.78% and a public holding of 20.22%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Pharmazz India?
Pharmazz India has a workforce of 37 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pharmazz India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pharmazz India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
